Imprimis clarified that its calcium di-sodium injection is priced at $495 for a five-day treatment. The company quoted the WHO's estimate of a 1000 mg to 2000 mg or more daily dose based on blood lead levels and body surface area. Meanwhile, Valeant's drug costs $27,000 currently.
The injectable formulation of Imprimis is available to patients only on patient-specific prescription, although in many states, hospitals, urgent care centers, poison control centers and physician offices can stock it for emergency uses.
With the FDA's policy limiting the use of Imprimis' cost effective treatment in emergency situation where medications are needed immediately, the company said it is hopeful that the FDA re-evaluates its policy, especially for emergent care conditions.
The only alternatives currently available to healthcare institutions are to purchase and stock Valeant's product or attempt to make it themselves and administer the drug without the necessary battery of safety tests that Imprimis completes prior to dispensing.
At time of writing, shares of Imprimis were down 3.07 percent at $3.17, and those of Valeant were down 0.7 percent at $21.25.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
